Long-term risk of heart failure in adult cancer survivors: a systematic review and meta-analysis
Authors' conclusion
HF is increased in adult cancer survivors, associated with cardiotoxic cancer therapy and standard risk factors.
Study context
- Population
- Adult cancer survivors (≥50 years old) ≥5 years after potentially cardiotoxic cancer therapy13 papers
- Participants
- 190,259 survivors
- Comparison
- Cancer survivors vs controls
- Outcome
- HF
Methodological detailsrandom effects model
- Random effects model
Pooled result
As reported in the abstract
HF risk in adult cancer survivors
Overall RR of heart failure (HF)
1.47
95% CI 1.17 to 1.86
Overall HF incidence rate
2.1%
HF incidence rate in the control arm
1.7%
Absolute risk difference
0.4%
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| HF, cardiotoxic treatmentvs cancer aloneSimilar risk | 1.46 (0.98–2.16) | |
| 0.512Relative risk (log scale) |
HF in breast cancer population (11 studies)
- Overall HF RR
- 2.57 (95% CI 1.35 to 4.90)
Heterogeneity, multivariable meta-regression
- Heterogeneity I2
- 77.2
- Age OR (95% CI 1.04 to 1.25), p=0.003
- 1.14
- Hypertension OR (95% CI 0.92 to 0.98), p<0.001
- 0.95
- Residual heterogeneity I2
- 28.7
- Follow-up duration OR (95% CI 0.97 to 0.99), p=0.047
Original publication
Long-term risk of heart failure in adult cancer survivors: a systematic review and meta-analysis. Heart. Published 22 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →